1 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow SR 48692: new trials by email Literature Review of SR 48692 trials Research Report on SR 48692
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide SR48692 - Lung Cancer, Pulmonary Neoplasms | Phase 2 / Phase 3 | Completed | Sanofi | 432 | 2002-10-01 | 2008-12-23 |
Lung Neoplasms (1) · Neoplasm Metastasis (1) · Small Cell Lung Carcinoma (1)
Sanofi (1)
Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Mexico (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · United Kingdom (1)